Eur Respir J 1999; 14: 678-685
Copyright © ERS Journals Ltd 1999
The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study
M Robinson,
E Daviskas,
S Eberl,
J Baker,
HK Chan,
SD Anderson,
and
PT Bye
It has been postulated that hypertonic saline (HS) might impair the antimicrobial effects of defensins within the airways. Alternative non-ionic osmotic agents such as mannitol may thus be preferable to HS in promoting bronchial mucus clearance (BMC) in patients with cystic fibrosis (CF). This study reports the effect of inhalation of another osmotic agent, dry powder Mannitol (300 mg), compared with its control (empty capsules plus matched voluntary cough) and a 6% solution of HS on BMC in 12 patients with cystic fibrosis (CF). Mucus clearance was measured using a radioaerosol/gamma camera technique. Post-intervention clearance was measured for 60 min, followed by cough clearance for 30 min. Neither mannitol nor HS improved BMC during the actual intervention period compared with their respective controls. However during the post-intervention measurement there was a significant improvement in BMC for both the mannitol (8.7+/-3.3% versus 2.8+/-0.7%) and HS (10.0+/-2.3% versus 3.5+/-0.8%). There was also a significant improvement in cough clearance with the Mannitol (9.7+/-2.4%) compared with its control (2.5+/-0.8%). Despite premedication with a bronchodilator, a small fall in forced expiratory volume in one second (FEV1) was seen immediately after administration of both the mannitol (7.3+/-2.5%) and HS (5.8+/-1.2%). Values of FEV1 returned to baseline by the end of the study. Inhaled mannitol is a potential mucoactive agent in cystic fibrosis patients. Further studies are required to establish the optimal dose and the long-term effectiveness of mannitol.
This article has been cited by other articles:

|
 |

|
 |
 
G. J. Redding, C. Kishioka, P. Martinez, and B. K. Rubin
Physical and Transport Properties of Sputum From Children With Idiopathic Bronchiectasis
Chest,
December 1, 2008;
134(6):
1129 - 1134.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Bartholdson, A. R. Brown, B. R. Mewburn, D. J. Clarke, S. C. Fry, D. J. Campopiano, and J. R. W. Govan
Plant host and sugar alcohol induced exopolysaccharide biosynthesis in the Burkholderia cepacia complex
Microbiology,
August 1, 2008;
154(8):
2513 - 2521.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Jaques, E. Daviskas, J. A. Turton, K. McKay, P. Cooper, R. G. Stirling, C. F. Robertson, P. T. P. Bye, P. N. LeSouef, B. Shadbolt, et al.
Inhaled Mannitol Improves Lung Function in Cystic Fibrosis
Chest,
June 1, 2008;
133(6):
1388 - 1396.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Donaldson, T. E. Corcoran, B. L. Laube, and W. D. Bennett
Mucociliary Clearance as an Outcome Measure for Cystic Fibrosis Clinical Research
Proceedings of the ATS,
August 1, 2007;
4(4):
399 - 405.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Grasemann, F. Stehling, H. Brunar, R. Widmann, T. W. Laliberte, L. Molina, G. Doring, and F. Ratjen
Inhalation of Moli1901 in Patients With Cystic Fibrosis
Chest,
May 1, 2007;
131(5):
1461 - 1466.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. H. Levin, S. Sullivan, D. Nielson, B. Yang, W. E. Finkbeiner, and A. S. Verkman
Hypertonic Saline Therapy in Cystic Fibrosis: EVIDENCE AGAINST THE PROPOSED MECHANISM INVOLVING AQUAPORINS
J. Biol. Chem.,
September 1, 2006;
281(35):
25803 - 25812.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Bolser
Cough Suppressant and Pharmacologic Protussive Therapy: ACCP Evidence-Based Clinical Practice Guidelines
Chest,
January 1, 2006;
129(1_suppl):
238S - 249S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. McShane, J.C. Davies, T. Wodehouse, A. Bush, D. Geddes, and E.W.F.W. Alton
Normal nasal mucociliary clearance in CF children: evidence against a CFTR-related defect
Eur. Respir. J.,
July 1, 2004;
24(1):
95 - 100.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R.C. Boucher
New concepts of the pathogenesis of cystic fibrosis lung disease
Eur. Respir. J.,
January 1, 2004;
23(1):
146 - 158.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G.F. Joos and B. O'Connor
Indirect airway challenges
Eur. Respir. J.,
June 1, 2003;
21(6):
1050 - 1068.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Mandelberg, G. Tal, M. Witzling, E. Someck, S. Houri, A. Balin, and I. E. Priel
Nebulized 3% Hypertonic Saline Solution Treatment in Hospitalized Infants With Viral Bronchiolitis
Chest,
February 1, 2003;
123(2):
481 - 487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Daviskas, S.D. Anderson, S. Eberl, H-K. Chan, I.H. Young, and J.P. Seale
Effects of terbutaline in combination with mannitol on mucociliary clearance
Eur. Respir. J.,
December 1, 2002;
20(6):
1423 - 1429.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Sarrell, G. Tal, M. Witzling, E. Someck, S. Houri, H. A. Cohen, and A. Mandelberg
Nebulized 3% Hypertonic Saline Solution Treatment in Ambulatory Children With Viral Bronchiolitis Decreases Symptoms
Chest,
December 1, 2002;
122(6):
2015 - 2020.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C F Robertson
How do we choose a therapeutic regimen in cystic fibrosis?
Thorax,
October 1, 2002;
57(10):
839 - 840.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P.G. Middleton, K.A. Pollard, and J.R. Wheatley
Hypertonic saline alters ion transport across the human airway epithelium
Eur. Respir. J.,
February 1, 2001;
17(2):
195 - 199.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Daviskas, S. D. Anderson, S. Eberl, H-K. Chan, and I. H. Young
The 24-h Effect of Mannitol on the Clearance of Mucus in Patients With Bronchiectasis
Chest,
February 1, 2001;
119(2):
414 - 421.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the European Respiratory Society.
|